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Introduction
eiving  cancer  diagnosis  can  be  devastating  for  many  patients  bui  thanks  [o
mcesincancertherapiesitisnotadeamsentcnceanymore.Cancersurvivdrates
increasingandlifeaftercancerisarealchanceformanypatienisworldwide.In
)pe,abouionethirdofcancerpatientshavearelative5-yearsurvivalrategreater
80  %  [1].  Similar  survivst  rates  are  seen  in  the  United  States,  Canada  and
Lrùia.  I.owcr suivivd  ra{es in developing countries  are  most likely due  io late
nosisandlimjtedavailabiliDofup-todaiestandaidticatmenB[2,3].
iltaly,everydayabout30newcasesofcancerarediagnosedinpatientsbelow
geof40yearsandmanyofthemarewomenwithbi.eastcancer.About10%of
stcancerdiagnosisoccursinpatienisyoungerihan40years[4].
neastcancerinyoungwomenisfrequcmlymoreaggressivethantumoumdiag-
]inolderwomen.Oftenmetastasesatloco-regionallymphnodesaredetectcd
agnosis  and  biological  and  molecular  characieristics  identify  phenotypes  M
prognosis[5].Asaconsequence.systemictieatmentsinadditiontolocalther-
mfiequenilyrecommended.Inspiteofthis,poorersurvivalratesandhigher
tfrecurrenceareieportedinthesesubgioupofpatients[6].
i.anks  to  adjuvant  therapies,  overall  and  disease-free  survival  are  improving
iineandmostofthepatientilongsurviveiobi.eastcancer.Chemotherapyand
rine  therai)y  extend  time  to  recurrence  bui,  on  the  other hand,  bring  about
short-   and   long-iem   side   effects.   Among   them,   ovarian   failure   with
iiuiemenopauseisparticularlyrelevanttoyoungwomen.Inthelastfewyears,
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in life has been observed  and man!
-        _---ia.:n. tt`pirfamilies [7l. l.
72
a  trend  towards  delaying  pregnancy  to  later  in  iiie  iias  _„  vvv__
womenreceiveadiagnosisofbreastcancerbeforecompletingtheirfamiliesmh
mthefrequencyofpregnancyinwomenaged#yeffiormorewas12%m
1990,16%in1996anditisestimatedthatwinamountto25%in2025m
Diagnosisandtreatmentofbreastcanceroftenthi.eatenfertility.Guidelineshigh
`:Fahs`ntchetr'eTt¥:nat:C:n°df:::C:Ssstngfwf'et:,?,:;'e,:tssstì:gw°en,:da°st°tì':::fae,::b°,:Tet|:=
preservationstrategies,inadditiontothechancesoffutureconception,pregnair!
Anintemet-basedmrvqreportsthatmorethan50%ofwommatthetimcd
and breastfeeding [8, 9].
diagnosisofbreastcancerhavefertilityconcems[10],bwlessthan10%ofw"
withpreviousbreastcancersubsequentlybecomepregn"Thisisaroundhalfùi
pregnancyrateseeninage-matchedgroupwithoutbreastca"[11].Severalstu+
iesshowdthatfertilitycounsellingremainsinadequateandlacksofastandardisd
approach[12|.ThefeffthatpregnancyafterbreastcancercouWworsentheprogm
sisdoesinterferewiththereproductivedesireofyoungwomenandimpairsfuu
ThereisincreasingevidenceinfavourofthefeasibilityandthesafèvofpT
conception.
nancyandbreastfeedingafterbreastcancer,therefore,wommwmahistopd
successfullytreatedbreastneoplasmshouldbegiventhepossibilùtoconcei%a-
ge, mother.
__----.-------_-`-==-
6.2       TheRelationship Between Breastcancer
and Pregnancy
Manyscientificevidenceslinkpregnancyandriskofbreastcancer.Severalepid}
miologicalstudiesshowedaprotectiveeffectofpregnancyagainstbreastc-
Tió-.ntprtiondoesnottakeplaceimmediately:forafewyeaftafterpregnant|• _ -:J---a  Thic du l ffect of Pl -The protection does not take piace iiiiiii.u,a„„ .  .__
thereisatransientincreaseofbreastcancerincidence.Thisdualeffectofpn}•.---. :.i an i rrpadriskforabout5-10yearsafl-
nancyonbreastcancerincidence.withanincreasedriskioraDoui|-„,v_
[ re  l   a  lrall>l.,1 ,.,. ~..___   _
-----.   f^ii^ujpd  hv  a  lifelong  protective  effect,  was  described  in  a_    .  __  :_^_,.acp  nf
population-basedstudyfromNorwayThisstudyreportedmincreaseofb
a  pregnancy,  followed  by  a  liieioiig  ijiu,..„ ,.,. ___  ,
•     . ' ---- '--.:no l vears after a full-term pregnancy, followed by long-
cancerincidencelasting3yearsafterafull-tempregnancy,followedbylong-
lation-based  study  l   NOTwa} .,,,,... __,       .
;eductionofrisk[13].
^n^th~Norwegianregistry-basedstudyinvestigatedtiBrelationshipbe`-               _ _____.  l f` o7n narolls wom l.
bi.eastcancerprognosisandreproductivefactomamong16,970parousmm
Another Norwegian  regi>ii y-i,a..u  u.__,
" "    ^-ai`tcino  the  re|ationship  between  Parity,  ageDi.e >` iai.--|  ri- ---
invasive  breast  tumour  [14].  Analysing  the  reiationsnip  ij.iw -...  r___,,    .
breastcanceroutcome,itwasobservedthatwhendiagnosisoccursbeforemea£•     ` .---.--- a :n ujr`men with high parity compared with those wim.         ,     _  _L_~-^,
50years,survivalisworseinwomenwimhighpanvcompdic;uw,,,...___
Dre L lalll.L V..,_..__ 7
panty.Thisislikelyduetoacombinationofgeneticfactors.moleculucharaciaT
ticsofbreasttumoursinyoui`gpatientsandhormonalmilieu.Nocle"uas-
tionwasobservdbetweenpariwandbreastcancersurvivalwhendiagnosiso-
inwomenwhowere50yeai.sorolder.
Severalstudiestridtoexplainthistime-dependenteffectofpregnanqonbn-
cancerrisk.MoleculmsWlinkedpostnatalmammaqinvolutionprocess-
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susceptibility to neoplastic evolu(ion. It is hypothesised that angiogenesis, alteration
of extracellular matrix  and  inflammatory prmess  are involved  in  this  mechanism.
The stroma of the mammary gland is greatly modified depending on endocrine sta-
tus  and  reproductive  factors.  Post-lac[ational  tissue  remodelling  may  provide  a
break in the natural stromal barriers that suppress tumour cell motility and invasion
with increased risk of tumour progression [ 15]. Another hypoihesis involves mam-
mary  s(em cells.  In  mouse  models,  it  was  observed that  mammary  s(em cells  a(e
highly responsive to steroid hormone signalling, despite their ER and PgR pheno-
iypes. Following pregnancy, it was registered a transient increase in the number of
mammary stem cells. which may indicate a cellular basis for the short-term increase
in breast cancer risk  [16].
Pregnancy-related  hormonal  changes  seem  to  be  involved  particularly  in  the
long-tem  protective  effect.  Preclinical  models  demonstrated  that  high  doses  of
es(radiol  induce  apoptosis  in  long-term  deprived,  ER-positive  breast  cancer  cell
lines [ 17]. Activation of caspases via the Fas/Fal pathway appears to be involved in
the  promotion  of apoptosis due  to estradiol.  me  long-term oestrogen deprivation
seems to sensi[ise breast cells to estradiol pro-apoptotic effect, with a reduction of
number and growth of cancer cells in vitro. Response to estradiol depends on the ER
subtypes expressed  by  the cells.  Breast cells expressing  ER-P undergo  apoptosis,
whereas cells expressing ER-oi are protected from apoptosis.  A comparative study
analysed the oestrogen receptor (ER) expression in nulliparous and parous women.
Compared to nulliparous women, a lower expression of ER-a and a higher expres-
sion of ER-B was observed in parous women [ 18]. Other authors suggested the fetal
antigen hypothesis. Clinical studies found that a high percentage of parous women,
but not nulliparous women, show evidence of immunisation to antigens located on
breast cancer cells. Fetal cells and breast cancer cells share common antigens:  the
immune response exerted by matemal immunity against fetal cells may be extended
against cancer cells [ 19].
6.3       PregnahcyAf(er Breastcancer
Several case-control and population-based studies have been perfomed with me aim
of understanding  the  prognostic  impaci  of pregnancy  after breast cancer.  None  of
these  studies  demonstrated  a  negative  impact  of a  subsequent  pregnancy  [20].  In
particular, a meta-analysis was perfomed (o investigate the impact of pregnancy on
overall  survival of women with previous breast cancer [21]. Fourteen studies were
included  in  the  meta-analysis,  with  a total  number of  1,244  patients  who became
pregnant after breast cancer and  18,145  patients  who did not.  It was observed that
women who became pregnant after adequate treatments for breast cancer had a sta-
tistically  significant  improvement  in  overall  survival  as  compared  to  the  control
group   [pooled   relative   risk   (PRR):   0.59;   confidence   interval   (CI):   0.50JO.70].
Analysing each study singularly, 8 siudies reported a significant survival advantage
for subsequent pregnancy, whilst the remaining 6 studies showed a not statistically
significant trend in favour of pregnancy.
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Studyingtheimpactofpregnancyonprognosis.the"healthymothereffect"mm
be kept in mind. This is a relatively old concept introduced by Sankila in  1994, .
explainapotentialconfoundingfactorintheinterpretationoftheobservedeffectof
pregnancyinwomenwithcancer[22].Itexpressesthepossibilitythatthosewom
who got pregnant after breast cancer are a subgroup of patients free of relapse anl
healthier than the others. mis could introduce a selection bias: women who becom.
pregnantafterbreastcancerhavebettersurvivalbecausetheybelongtoasubg"i
of patients  with  good  prognosis,  independently  and  not  because  of a  protecti-
effect of the pregnancy.
Inthepreviouslycitedmeta-analysis,asubgroupanalysisinordertoovercon
this bias was performed. The outcome of women with pregnancy after breast ca-
cer was compared with  the outcome of controls  who were known to be frec al
relapse. A not statistically significant trend favouring pregnancy after breast ca+
cer was still observed [21]. Even if selection bias may partially contribute to tl
conclude that pregnancy is s±
in  women  with  a  history  of  breast  cancer  and  does  not  increase  the  risk
recurrence.
risk of death reduction, it seems still reasonable to
In  spite  of this.  a  possible  negative  impact  of  pregnancy  on  breast  c:
particularly  in patients-with endocrine-responsive tumour,  is  still
concern. Recently, a study with the aim of investigating the effect of pregn
prognosis,
in  women  with  breast cancer according  to oestrogen  receptor status  was c
àLcted by Azim et a,.  [23].  In the three subgroups  ,oestrogen receptor-Posi
cohort.  oestrogen  receptor-negative  cohort  and  all  patients)  no  difference
disease-free su-rvival was observed between women who become pregnant
those who did not conceive. Further, the pregnant group had better overall
vival,  again  with  no  interaciion observed according  to ER  status  [23].  In  s
mary.  the  study  indicates  that  pregnancy  is  not  protective  against  a  relapsc
patients with endocrine-sensitive tumour, but at the same time it does not e
a detrimental effect.
Afurtherpointofdiscussionisthetimeintervalbetweentheendofantineo
tic treatments and pregnancy. Several studies analysed this relationship with i
sistent results.  A  significant survival  improvement was observed only  for w
who conceive after Z4 months or more (Table 6.1 ). A not significant protection
Table 6.1    Cox.s proportional hazard model for survival in womcn with breast cancer with
dependent variable stratified by time from diagnosis
Beta c¢fficient
Time to subsequent
(monms)pregnancy
Hazard ratio (95 qr
Cl)
2.20 (0,14-35.42)
0.45 (0.16-1.28)
0.48 (0.270.83)
(Each stratified model adjusted for age. lymph node status. and tumor size)
Modified   from   lvcs   A.   et   al.   Pregnancy   after  breast  cancer:   population-based   study.
2007:334:194
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observed  for women  who delayed  pregnancy  for ai least 6  months  [24].  A  large
population-based study corroborates the theory that the risk of dying decreases with
increasing the gap between diagnosis and childbirth [25].
The optimal  timing  of pregnancy  after breast  cancer is  sti]]  undefined and  the
decision depends on patient's prognosis, age and personal condition. Because of the
reassuring studies on patients who get pregnant 2 years and more after breast cancer
and the observation that recurrences occur more frequently in the first few years, a
delay of 2-3 years is conventionally recommended.
TTiis time interval would also allow to recover from chemotherapy-induced ovar-
ian toxicity.  Women with  ER-negative  breast cancer should be  advised  to wait at
least 6 months from the end of treatments before conceiving, to avoid the possible
toxic effect of chemotherapy on growing oocytes.
As to ER-positive breast cancer, current guidelines recommend at least 5 years of
endmrine  therapy  [26].  Furthermore,  recent  evidence  suggests  that  10  year§  of
tamoxifen confer even greater protection [27]. Because of me teratogenetic effects
of tamoxifen,  pregnancy  during endocrine therapy is contraindicated  and an off-
therapy period of 3i months is recommended before conceiving. But the reproduc-
tive potential is declining year by year, because of the physiological loss of ovarian
reserve and the harms of chemotherapy. The feasibility of a temporary break of the
homonal therapy allowing to conceive and have a fiill-term pregnancy, with subse-
quent completion of endocrine treatment is under investigation. A prospective study
of the Breast lntemational Group and North American Breast Cancer Group (BIG-
NABCG)  is  currently  ongoing.  investigating  the  clinical  and  biological  features
contributing  to  a  safe  and  successful   pregnancy   in  ER-positive  breast  cancer
pa(ients. The  analysis will  f«us on both oncological  outcomes  (local  and distant
recurrences and survival) and obstetrical outcomes (sponianeous abortion, preterm
delivery,  in(rauterine growth restriction,  low weigh( at birth,  fe(al  malformations).
Secondary endpoints of the study are the feasibility and the impact of a temporary
break of endocrine therapy to allow conception and the optimal duration of subse-
quent homonal therapy after delivery and breastfeeding [28].
6.4      0bstetrical and Neonatal outcome
One of the unnamed concems that patients face is the fear of a potential teratogenic
effect of antineoplastic treatments on the offspring. Few data are available on birth
outcomes in breast cancer survival: however, no excess risk for the newbom health
is suggested [28].
Some  studies  found  a higher rate of abortion  than  in general  population.  This
information may be biased because most of the studies did not discriminate between
spontaneous  and  induced  abortion.  When  this  issue  was  considered,  the  risk  of
spontaneous  abortion  did  not  seem  to  be  higher  in  breast cancer patients  than  in
general  population.  On  the  contrary,  the  rate  of induced  abortion  is  consistently
higher, suggesting that unceiiainties of patients and physicians about safety of preg-
nancy  after breast cancer often  lead  to  dramatic  choices  [29].  Studies  comparing
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disease-free surviva] in patients who completed their pregnancy to term and pati
who had an  abortion  found a  not  statistically significant trend towards better
come in women who had a full-term pregnancy [23].
Two large studies assessed the obstetrical and neonatal outcomes of pregnanci-
following  breast  cancer.  A  Danish  nationwide  cohort  study  investigated  w
matemal  breast cancer affects  birth  outcome  [30].  Data  about  pregnancies of 2-
women  with  a  his(ory  of breas( cancer were  matched  with  a comparison cohoit
10,453  women  belonging  to general  population.  Similar rates  of low  birth  weigL
s(illbir(h and congeni(al abnormalities were observed in the two groups. A small -
not  sta(istically  significant  higher preterm  delivery  ra(e  was observed  in  the  b
cancer cohort. Mean birth weight was nearly 3,400 g in both groups, as well as m-
gestational age ai delivery. Different findings were reported in a Swedish cohort stn.
aiming to assess delivery risk and neonatal health [31 ]. Data were extrapola(ed fi-
the Swedish Medical Birth Regis(ry and the Swedish Cancer Regis(ry, including 3.
mothers with a history of breast caiìcer and 2,870,518 mothers belonging to ge
population.  An  increased  risk of delivery  complication,  caesarean  section,  p
delivery and congeni(al  malformations and no differcnce in low birth weight raòe
delivery  was  observed.  Authors  conclusion  is  that  pregnancy  after  breast  c
should be considered at high risk and therefore managed and surveilled accordindL
Usually women  with previous breast cancer are more  likely  to give birth ai
older  age  than  the  general  population.  Both  studies  point  out  this  differencc
matemal  age.  About 50  %  of women  in  breast  cancer cohort  are  35  years old
more at delivery, with a mean age of 34 years, whereas in the comparison group
figures are  1 1  % and 28 years, respectively [30, 31 ]. It is well known that pregn
at an old age is more susceptible to many comorbidities and complications as g
tional  hypertension,  preeclampsia,  gestational  diabetes  and  other  conditions
bring about high risk for pregnancy outcome and require special surveillance.
may partially explain the slightly higher rate of pregnancy complications re
in the Swedish study, but uncertainties still exists.
6.5       Breastfeeding After Breastcancer
Many factors, such as personal, cultural. social and environmental factors, influ
women's decision about breastfeeding.  Beyond these, breast cancer survivors
unique physical and emotional  factors that might impact their decision and ab
to breastfeed.
A qua]itative research explored by an interview the experience and the fec
about  breastfeeding  in  a  selected groiip of breast cancer survivors  [32].  Gene
patients alleged the wish to breastfeed, but also anxiety and concems about doing
This highlighis the  need of prenatal  education and information  io prepare me
spective mother to the challenges of breastfeeding.  Breast cancer survivors all
physical  and  emotional  problems,  mainly  because  they  had  to  rely  primaril}.
entirely on one brcast. Treatments for breast cancer can affect lactation. Proximit}.
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he surgical incision to thc nipple-aieo]a complex. dose and type of radia(ion therapy
nayreduceorinhibitlactation.mus,manypatientscanbreastfeedfromtheuntreatcd
ireast only, with consequent uncertainty about whether or not the milk supply would
e sufficient for the infant [32]. Failure to nurse from one breast should not affect the
ise of the other and me mother should be reassured about the adequacy of milk pro-
luction by a single breast, sufficient for the nutritional need of the newbom.
Another survey analysis was performed investigating the breastfeeding pattems
nd habits in breast cancer survivors [33]. Hypoplasia and hypotrophia of the oper-
ted and irradiated breast were observed, with consequent reduced milk production,
iipple pain, physical changes and discomfort during latching. Furthermore, a previ-
ius  mastectomy  was  associated  with  short-lasting  breastfeeding.  This  is  not  only
ustified by the fact that these patients have a single breast to nurse their babies, but
.lso women with previous breast conserving surgery used one breast only for lacta-
ion.  A possible altemative explanation is that body  image plays an important role
n the success of breastfeeding, and breast-conserving  surgery,  in  spite of mastec-
Dmy, may reinforce the feeling of matemal adequacy. A proper breastfeeding coun-
elling  is a key factor for successful  and prolonged breastfeeding  in breast cancer
urvivors.  This  experience  often  brings  about  a  psychological  rehabilitation  and
iatients express  satisfaction  to have been  able  to breastfed their babies, even  if it
equired efforts and sometimes milk supplement.
These results enlighten the reasons of breast cancer survivors to breastfeed and
he challenges which they will face and concem them. It is of the utmost importance
hat physicians provide practical  and continuous support to the mother, especially
luring the postpartum period.
Beyond  feasibility  the  safety  of  breastfeeding  after  breast  cancer  treatment
emainsanopenquestion.Severalstudieshavedemonstratedtheprotectiveeffectof
)reastfeeding on breast cancer risk in general population. A meta-analysis including
lata  from 47  epidemiological  studics, evaluating the  relationship between  breast-
•eeding and breast cancer, has demonstrated a 4.3 % reduction of the relative risk of
)reast cancer for each year that a woman breastfeeds [34]. In order to reduce biases,
;tratifications  for  age,  parity,  ethnicity  and  age  at  fìrst  delivery  were  perfomed,
natching women who breastfed and who did not breastfeed on the basis of the same
:haracteristics. The conclusion was that the benefits are statistically significant and
)reastfeeding should be encouraged.
While  there  is  evidence  that  breastfeeding  reduces  breast  cancer  incidence  in
5eneral  population,  there  are  no  solid  epidemiological  data  about  breastfeeding
Lfter breast cancer. A retrospective case-control study investigated the survival rate
)f patients  treated  for  breast  cancer  who  subsequently  became  pregnam  [35].  A
•ecent re-analysis of those data was performed,  specifically focused on the role of
)reastfeeding. A better survival was suggested in women who breastfed. mese data
:ould be biased, but it may be supposed mat breastfeeding does not have a detrimen-
al effect on breast cancer outcome [36].
The  mechanisms  undemeath  the  asscx:iaiion of breastfeeding  and  reduction of
)reast cancer incidence are not known. Several hypotheses were expressed in vari-
m  studies and were  synthesised  in  a review  article  [36].  Some data suggest that
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lactation may reduce the carcinogens level in the breast. Another hypothesis is the
suck]ing-related blockage of the hypothalamus-pituitary axis leading to lactationa)
amenorrhoea. From animal  models, it was hypothesised that differentiation of the
mammary gland as observed during pregnancy and lactation protects from neoplas-
tic  evolution. The  role of prolactine  has  been  widely  studied but with conflicting
results. and the impact of this hormone on initiation and promotion of breast canccr
in humans remains unclear.
Epithelium  changes  and  stromal  ac(ivation  which  occur  in  remodelling  breast
tissue may be associated with a temporary increase in breast cancer incidence. This
observation  recommends  a  thorough  follow-up of women  with  history  of breasi
cancer after pregnancy or lactation. Patients and physicians often tell of the fear of
a delay in diagnosis in case of tumour recuiTence. Lactation does not interfere with
clinical  and radiological evaluation of the breasts.  Ultrasound exam can be safel}.
perfomied and in case of suspicion, mammography or breast magnetic resonancc
imaging can be performed after having drained the lactating breasts [36].
Despite uncertainty, the benefits of breastfeeding to the baby and the mother arc
well established. Newboms who are breastfed are pmtected from infections in the
short period and are less susceptible to develop autoimmune diseases and metabolic
disorders at adult age. Furthermore, a benefit in neu":ognitive developmem of tlìc
baby breastfed has been suggested. Breastfeeding bears several advantages for the
mother as well. Women who breastfeed have better control of postpartum bleeding.
retum swiftly at the usual weight and ane heavily gratified by the emotional bo")
which is created with her baby.
In conclusion, current evidence suggests that breast cancer survivors who wish to
breastfeed, should be encouraged and supported in their efforts.
6.6       Childbearing Attitudes ofYouhg Breast
Cancer Survivors
Many studies have shown that pregnancy and paienthood are two important issucs
for young women  with breast cancer.  As breast cancer-related mortality declines.
the impact of anticancer treatments on reproductive potential  is getting more rele-
vant, and fertility impairment may worsen the quality of life in a growing number or
patients.  For  some  young  breast cancer survivors,  the threat to their childbearing
plans has major emotional and psychological consequences. Literature and clinical
practice demonstrate that some women remain fertile and have a spontaneous preg-
nancy after a history of cancer. Additionally, (he advent of advanced assisted repfù
ductive  technology  within  the  oncology  field  has  made  fertility  preservation  an
option for women, prior to the initiation of (reatments. As known. other options afc
available  for infertile women,  such as  adoption and third-party reproduction, bui
most couples crave biological offspring.
Several studies showed that the risk of early menopause and infertility are causes
of concem for about the half of young women who receive breast cancer diagnosis.
Some pa(ients reported that this fear conditioned treatment decisions [37]. Infertilip
t,.
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in cancer pa(ients is associated. more frequently than in general population, to anxi-
ety. depressive symp(oms and sexual impairment which have a negative impact on
the quality of life.
But  even   when   fertility   is   preserved,   other  concems   upset  breast  cancer
patients. Women fear that the child might be bom wi(h a birth defec( because of
the chemotherapeutic agents they received. They are anxious about a shorter life
expectancy  and  are   afraid  of  having   not  enough  energies   to  raise  children.
Furthemore. women feared that the offspring would have a greater susceptibility
to cancer [38].
On the other hand, some patients peiceive the benefits that could be achieved by
having  cmldren  after breast cancer treatmeni  Raising a child can  be  a powerful
motivator to stay alive and healthy, ii may strengthen the relationship with the part-
ner, it brings back normalcy in their life and it would restore the sense of femininity
and sexuality [39]. Breast cancer survivors who are disease-free often feel healthy
enough  (o consider a pregnancy.  This is called a reasonable  wellness, which  may
express the ethical guide into the difficult choice of getting mother.
In clinical practice, gynaecologists and oncologists are frequently faced with the
issue of educating women about childbearing after breast cancer.  However,  some
studies suggested that these professionals often feel discomfort and lack of knowl-
edge about how .o best educate women with cancer-related fertiliLy ma((ers, leaving
women's  fertility  concems  poorly  addressed.  Attending  physicians  may  perceive
the  fertility  preservation  as  a  low  priority  issue,  compared  with  the  (rea(mem  of
cancer or  they  could  fear that  fertility  preservation  techniques  may  dwindle  the
efficacy of anticancer treatments. Presently, there are guidelines stressing the need
to   communicate   with   and   educate   young   patients   regarding   fertility   issues.
Oncologists should refer interested and appropriate patients to reproductive special-
ists as early  as possible, to allow  a rapid access to fertility preservation  strategies
and to avoid delaying the chemotherapy onset [8, 9].
6.7       Breastcancer, Pregnahcyand Breastfeeding
in BRCA1 /2 Mutation Carriers
Reproductive factors influence the risk of breast cancer in the general  population,
but few data are available in the selected group of women with mutations in BRCAl
and  BRCA2 genes.  BRCAl  and BRCA2 are .umour suppressor genes which are
involved in multiple processes, including DNA damage repair and recombination,
and regulate noimal cell differentiation. During pregnancy and breastfeeding, breast
cells divide and differentiate;  thus,  it could be  supposed  that reproductive  factors
have different impacts on breast cancer risk in die BRCA mutation carriers and in
general population.
A  large retrospective cohort study including women carrying BRCAl/2 muta-
tions investigated the impact of pregnancy on breast cancer incidence [40]. No dif-
ference  was  found  between  parous  and  nu]liparous  women,  and  the  same  results
were observed  in BRCAl  and BRCA2 mutation carriers.  It does no[ appear that
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parity  per  se  influences  the  risk  of  breast  cancer  in  this  particular  subgroup  of
Women.
Inconsistent  resul.s  aic  reported  about  the  asscx:iation  between  bieastféeding  and
breasi cancer risk. Some evidences suggest a protective effects of breastféeding, even
strongerthaningeneralpopulation,buton]yamongBRCA1mutationcarrieis[41,42].
It is known that hereditary breast cancer is different from  sporadic tumour and
differences are observed between breast cancer patients with BRCAl  and BRCA2
mutations as wel]. This might suggest that the biological pathway for carcinogene-
sis is differen[ for these two genes.
Our knowledge about the impact of pregnancy after breast cancer in BRCAl/2
mutation carriers is even poorer. This is partly due to the small proportion of women
carrying mutations in these genes. The question is sensible, because of the iypical
early  age  of onset  of hereditary  breast  cancer.  A  multicenter,  case-control  study
which included women known to carry a BRCA  1  or BRCA 2 mutation and history
of breast  cancer  has  been  published  recently  [43].  The  cases  were  patients  witti
pregnancy-associated breast cancer or pregnancy followjng breast cancer. The con-
trols  were  selected  among  patients  who  did  not  get  pregnam  after  breast  cancer
diagnosis and who were alive and recurrence-free at the time of the delivery of thc
baby in the matched group,  in order to reduce potential confounding bias, such as
the  healthy  mother effect.  The  15-year survival  was  excellent  in  the  two groups.
around 90 %, and no significant difference was observed between cases and controls
after adjustment for several prognostic factors. Despite the limitations of the study`
first of all the small sample size, these results are encouraging and future research is
recommended to prove the not detrimental effect of pregnancy after breast cancer in
this particular subgroup of women [43].
There  is  an  issue  in  BRCAl/2  mutation carriers  that deserves special  consider-
ation. Some studies suggested that the deficient DNA repair mechanism due to muta-
tions  in  BRCA   1   and  BRCA  2  genes  may  make  oocytes  more  susceptible  to
DNA-damaging  agents.  Furthemore,  it  has  been  speculated  that  BRCA  mutation
carriers may have a lesser ovarian reserve than general population and undergo prc-
mature menopause.  As a consequence, BRCA  mutation carriers may be more sus-
ceptible  to chemotherapy-induced gonadotoxicity  with  severe ovarian  reserve loss
[44]. Diagnosjs of brcast cancer in a young patient wim BRCA mutation raises con-
cems about her future fertility. A trend towards earlier referral to fenility specialists
underscores the importance of this issue.  However,  the better approach in this par-
ticular group  of patients  is  not  an  easy  choice.  On  one  side  data  suggest  a  pcxM
response  to ovarian  stimulation  for oocyte  retrieva]  and cryopreservation.  pariicu-
larly in BRCAl  mutation carriers; on the other side ovarian tissue cryopreservation
for  BRCA  mutation  carrier is  disputed  because  of the  risk  of ovarian  cancer and
lastly the efficacy of temporary ovarian suppression with GnRH agonists is still con-
(roversial  [44].
AIl  these  findings  suggest  that  BRCA  mutation  carriers  may  have  a  shorter
reproductive life, and thjs should be taken into account in the management of young
breast cancer patients who desire a future pregnancy. Whether or not the low ovar-
ian reserve and poor response to ovarian stimulation may reduce the fertility poten-
tial of women with BRCA mutations is still unknown and further research is needed.
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